
GW Pharmaceuticals stock initially popped, then toppled, Monday after European regulators approved the biotech company’s CBD oil in two seizure disorders. Cannabidiol, the long-winded name for CBD, is an active ingredient in cannabis. GW Pharmaceuticals’ Epidyolex is the first CBD oil derived directly from the cannabis plant to gain approval in Europe.
Leave a comment